The Spanish Agency for Medicines and Health Products (AEMPS) has ordered the withdrawal from the market of six batches of Solsint (levothyroxine sodium) A quality defect that "does not pose a vital risk to the patient", according to the AEMPS statement. Solsint is used as replacement therapy for thyroid hormone deficiency in cases of underactive thyroid gland.
It is also indicated for the prevention of goiter recurrence after surgery in patients with normal thyroid function.